Medical Pharmacology Chapter 36:  Antiviral Drugs

Previous Page Page Forward
Section Table of Contents
Site Table of Contents

Previous Page

Page Forward

Section Table of Contents

Site Table of Contents

References

  1. Acheson NH  Chapter 1 (in Acheson NH,  Fundamentals of molecular virology, 2nd edition) p. 13 2011.

  2. Wang F Kieff E Medical Viriology, Cahpter 177 Section 11:  Viral Diseases:  General Considerations (in Harrison's Principles of Internal Medicine, 18th edition, Longo DF Fauci AS Kasper DL Hauser SL Jameson JL Loscalzo J, eds) McGraw-Hill, New York, 2012, pp 1432-1433.

  3. Jones M HIV Membrane Fusion Panel (first two steps, see original reference for all steps). "1.  Initial interaction between gp120 and CD4. 2. Conformation changes in gp120 allows for secondary interaction with CCR5.http://en.wikipedia.org/wiki/HIV#mediaviewer/File:HIV_Membrane_fusion_panel.svg ; http://en.wikipedia.org/wiki/HIV

  4. Karlsson GB Fouchier RAM Phogat S Burton DR Sodroski J Wyat RT Nature Reviews Micobiology 6, 143-155 (February 2008). http://www.nature.com/nrmicro/journal/v6/n2/fig_tab/nrmicro1819_F4.html

  5. Fusion of virus membrane with host cell membrane ViralZone, Swiss Institute of Bioinformatics ViralZone 2011

  6. Flexner C Chapter 59.  Antiretroviral Agents and Treatment of HIV Infection (in Goodman & Gilman's The Pharmacological Basis of Therapeutics, 12 e, Brunton LL Chabner BA Knollmann BC, eds) The McGraw-Hill Companies, Inc, 2011.

  7. Eckert DM Kim PS Design of potent inhibitors of HIV-1 entry from the gp41 N-peptide region. PNAS (USA) 98(20):  11187-11192, September 25, 2001

  8. Harrison S (Harvard) Part 2:  Viral membrane fusion, iBiology (IBioSeminars:  Seminars from the World's Top Biologists, https://www.youtube.com/channel/UCsvqEZBO-kNmwuDBbKbfL6A);  https://www.youtube.com/watch?v=qcepGvFUM38

  9. LaBonte J Lebbos J Kirkpatrick nature Reviews Drug Discovery 2, 345-346 (May 2003). (Slight modification of Fig. 1) http://www.nature.com/nrd/journal/v2/n5/fig_tab/nrd1091_F1.html; Original figure attribution:  Kilby JM Hopkins S Venetta TM DiMassima B Cloud GA Lee JY Alldredge L Hunter E Lambert D Bolognesi D Matthews T Johnson MR Nowak MA Shaw GM Saag MS Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat. Med 4(11): 1302-1307, 1998. http://www.ncbi.nlm.nih.gov/pubmed/9809555

 

Disclaimer

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.